KALA Share Price Performance
US$7.38
1.63 (28.35%)
Price US$7.38
Share PriceUS$7.38
KALA Community Narratives
There are no narratives available yet.
Recent KALA News & Updates
No updates
KALA BIO, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -5.53
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 536.5%
KALA BIO, Inc. Competitors
About KALA
- Founded
- 2009
- Employees
- 38
- CEO
- WebsiteView website
KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company’s lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
U.S. Market Performance
- 7 Days: 0.2%
- 3 Months: 12.2%
- 1 Year: 19.9%
- Year to Date: 7.6%
The Consumer Staples sector gained 3.2% while the market remained flat over the last week. More promisingly, the market is up 20% over the past year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›
This week, we are weighing up the potential productivity gains vs job losses and economic disruption that the global economy could face over the next decade and beyond.
Continue reading